Growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging. The growth in research funding and rising government funding and investment in regenerative medicine research will also support the market growth in the coming years. However, the high cost of high-content screening systems is limiting the overall adoption of these products.
According to the WHO, as of September 29, 2020, there were 33,249,563 confirmed cases of COVID-19, including 1,000,040 deaths, with the highest number of deaths in the Americas, followed by Europe and Southeast Asia. Furthermore, due to the COVID-19 pandemic, governments across the globe have announced country-wide lockdowns as well as social distancing measures to prevent the collapse of their health systems.
For More Info @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483
Live cell imaging systems, including advanced microscopy systems, help researchers investigate cellular behavior during viral research. Biomedical research requires the analysis of enormous amounts of data to develop vaccines. Therefore, major live cell imaging system providers, such as Leica Microsystems (Germany) and CytoSMART Technologies (Netherlands), have donated live cell imaging systems to assist COVID-19 researchers.
The normalization of the global economy will slowly increase the demand for live cell imaging systems in non-COVID-related research activity labs, leading to market growth from the first quarter of 2021. Furthermore, players operating in the market are altering their strategies, for both long-term and short-term growth, by tapping the research market and developing innovative products to combat the pandemic.
The traditional method of toxicity and drug safety studies involves the screening of large libraries through high-throughput screening. This method is expensive, has a low success rate, and is resource- and time-consuming.
The use of HCS makes the drug development process more time- and cost-efficient. Owing to these factors, the adoption of high-content screening for toxicity studies is expected to increase during the forecast period. This, in turn, is expected to drive market growth as live cell imaging is used in HCS to identify meaningful information from complex systems such as in vitro, in vivo, and ex vivo systems.
Running live cell imaging experiments successfully can be a major challenge. The conditions under which cells are maintained under microscopes decide the success or failure of the experiment. Therefore, maintaining living cells on slides is the most crucial part of the experiment.
